chlormadinone
Chlormadinone acetate (CMA) is a derivative of naturally secreted progesterone that shows high affinity and activity at the progesterone receptor. It has an anti-estrogenic effect and, in contrast to natural progesterone, shows moderate anti-androgenic properties. CMA acts by blocking androgen receptors in target organs and by reducing the activity of skin 5alpha-reductase. It suppresses gonadotropin secretion and thereby reduces ovarian and adrenal androgen production. CMA shows high contraceptive efficacy by inhibiting ovulation due to its ability to suppress or disrupt endogenous gonadotropin secretion and, by this, inhibits follicular growth and maturation. In addition, it suppresses endometrial thickness and increases the viscosity of cervical mucus. Chlormadinone acetate was withdrawn from the market in the USA, but it is still being used in Europe under the name Belara. — NCATS
Clinical trial activity
4 trials · 4 clinical orgs · 0 marketing orgs
Earliest trial started Feb 1, 2006 (NCT00842140)
Timeline
No events for the selected filters.
Indications
Approved for
Mechanism of action
- Progesterone receptorMODULATOR
PGR modulator
Chlormadinone acetate (CMA) shows high affinity and activity at the progesterone receptor. It has an anti-estrogenic effect and, in contrast to natural progesterone, shows moderate anti-androgenic properties. CMA acts by blocking androgen receptors in target organs and by reducing the activity of skin 5alpha-reductase. It suppresses gonadotropin secretion and thereby reduces ovarian and adrenal androgen production.
Chlormadinone acetate has a strong affinity for the progesterone receptor, one-third higher than natural progesterone.
Chemistry & pharmacology
SMILES
CC(=O)[C@@]1(O)CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C- Mol. weight
- 362.89 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaChlormadinone ↗
- NCATSSDS4N642GG ↗
- ChEMBLCHEMBL1697830 ↗
- ChEMBLCHEMBL110691 ↗
Also known as
- chlormadinon
- chlormadinon acetate
- chlormadinone
- chlormadinone
- chlormadinone
- chlormadinone
- chlormadinone
- chlormadinone
- chlormadinone
- chlormadinone
- chlormadinone acetate
- chlormadinone acetate
- chlormadinone acetate
- chlormadinone acetate
- clormadinone
- clormadinone
- menstridyl
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01608698 | Phase 4 | Jun 1, 2012 | Mahidol University |
| NCT00844012 | Phase 4 | May 1, 2009 | Magna Graecia University |
| NCT01123538 | Phase 4 | Dec 1, 2008 | University Hospital of North Norway |
| NCT00842140 | N/A | Feb 1, 2006 | University of Sao Paulo |
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Magna Graecia University | Academic/Hospital | 1 | 1 | 1 | 2009 |
| Mahidol University | Academic/Hospital | 1 | 1 | 1 | 2012 |
| University Hospital of North Norway | Academic/Hospital | 1 | 1 | 1 | 2008 |
| University of Sao Paulo | Academic/Hospital | 1 | 1 | 1 | 2006 |